2026年11月4日星期三
M
Chroniques universelles
Flash info mondial
Nintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Source Nature 医学研究il y a 6 jours
Résumé du contenu

Ce site ne fournit qu'un index de titres et de résumés ; le contenu complet et les droits d'auteur appartiennent à l'éditeur d'origine. Veuillez cliquer sur le lien original pour lire.

Aller à l'article original
Chaîne d'appartenance
Santé
Région d'appartenance
Perspective mondiale
Langue de l'original
English
Numéro d'entrée
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · Chroniques universelles